HOME PAGE
COMPANY PROFILE
SCIENCE
PIPELINES
PARTNERSHIP
NEWS
CAREERS
CONTACT US
中文
EN
菜单
HOME PAGE
COMPANY PROFILE
Company Introduction
Company History
Management Team
NEWS
Neurophth News
SCIENCE
Gene Therapy
R&D Platforms
CMC Platforms
PIPELINES
Pipeline
Leber’s Hereditary Optic Neuropathy
Autosomal Dominant Optic Atrophy
Optic Nerve Injury
Vascular Retinopathy
CAREERS
Employee development
Working at Neurophth
Compensation & Benefits
CONTACT US
PARTNERSHIP
中文
EN
NEWS
2023-03-08
Maltese Patient Received World's First ND1-LHON Gene Therapy Injection Donated by Neurophth in China
2023-02-22
Commercialization of Gene Therapy is coming soon: Neurophth Completes Patient Enrollment for Phase III clinical trial for the gene therapy treatment of LHON
2022-12-21
1st LHON INTERNATIONAL FORUM
2022-12-20
41st Annual J.P. Morgan Healthcare Conference 2023 is approaching
2022-12-19
Neurophth Receives IND Clearance from FDA for AAV-ND1 Gene Therapy of LHON
2022-10-13
Special interview with Dr. Satoshi Kashii on World Sight Day
2022-09-27
Neurophth announces first patient dosed in Phase III clinical trial for the gene therapy treatment of LHON
2022-09-21
Special interview with Dr. Patrick Yu-Wai-Man on International LHON Awareness Day
2022-07-29
Neurophth Ranked as One of the MIT 50 Smartest Companies 2021
1
2
3
4
下一页